1. Hsa_circ_0003195 as a biomarker for diagnosis and prognosis of gastric cancer
- Author
-
Junming Guo, Dongnan Ma, Zhe Li, Yibo Ma, and Weiliang Sun
- Subjects
Lymphatic metastasis ,medicine.medical_specialty ,Gastroenterology ,Metastasis ,Stomach Neoplasms ,Surgical oncology ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,In patient ,Survival analysis ,Receiver operating characteristic ,business.industry ,Cancer ,RNA, Circular ,Hematology ,General Medicine ,Prognosis ,medicine.disease ,digestive system diseases ,Oncology ,Lymphatic Metastasis ,Biomarker (medicine) ,Surgery ,business - Abstract
Recent studies have shown that circular RNAs (circRNAs) are closely related to the occurrence and development of gastric cancer. In this paper, we analyzed the value of hsa_circ_0003195 in diagnosis and prognosis of gastric cancer. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to determine the level of hsa_circ_0003195 in 100 paired gastric cancer tissues and paracancerous tissues, 74 paired fasting plasma from gastric cancer patients before and 10 days after operation, and 74 fasting plasmas from healthy controls. A receiver operating characteristic (ROC) curve was generated to evaluate the diagnostic value. The survival analysis and Cox proportional-hazards model were used to evaluate the efficiency of hsa_circ_0003195 in predicting overall survival (OS) in patients with gastric cancer. The expression of hsa_circ_0003195 was down-regulated in gastric cancer tissues and plasma from patients with gastric cancer. The expression level of hsa_circ_0003195 was correlated with differentiation, TNM stages, lymphatic metastasis, and distal metastasis. The area under the ROC curve (AUC) of tissue and plasma hsa_circ_0003195 was 0.684 and 0.695, respectively. The plasma hsa_circ_0003195 can be used as predictors of survival of patients with gastric cancer. Hsa_circ_0003195 may be a new diagnostic and prognostic marker of gastric cancer.
- Published
- 2021